ProPhase Labs, Inc. (PRPH)
D
Pipeline Grade
Financial Position (from SEC Filings)
$0.2M
Cash & Equivalents
$0.8M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$1M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-03-01 | Phase2 Readout | — |
| 2027-04-15 | Phase2 Readout | — |
Active Clinical Trials (5)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07046260 | Prospective Study to Assess a Diagnostic Aid for Cancer | OTHER | Recruiting | 1,650 |
| NCT05837325 | Is the AMH Intrafollicular Level a Predictor of the Ploidy Status of the Blastocyst? | OTHER | Recruiting | 300 |
| NCT03541083 | Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. | PHASE2 | Active Not Recruiting | 71 |
| NCT07409103 | A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients ... | PHASE2 | Recruiting | 180 |
| NCT05787574 | A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PI... | PHASE2 | Recruiting | 39 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.